[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011139251A1 - Pharmaceutical compositions comprising cefditoren pivoxil - Google Patents

Pharmaceutical compositions comprising cefditoren pivoxil Download PDF

Info

Publication number
WO2011139251A1
WO2011139251A1 PCT/TR2011/000125 TR2011000125W WO2011139251A1 WO 2011139251 A1 WO2011139251 A1 WO 2011139251A1 TR 2011000125 W TR2011000125 W TR 2011000125W WO 2011139251 A1 WO2011139251 A1 WO 2011139251A1
Authority
WO
WIPO (PCT)
Prior art keywords
cefditoren pivoxil
sodium
diluent
cefditoren
carbonate
Prior art date
Application number
PCT/TR2011/000125
Other languages
French (fr)
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11724820.3A priority Critical patent/EP2566451B1/en
Publication of WO2011139251A1 publication Critical patent/WO2011139251A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to water dispersible forms comprising cefditoren pivoxil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof.
  • Cefditoren pivoxil is a third generation cephalosporin, which has the chemical name (6R,7R)- pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3 -[(Z)-2-(4- methylthiazol-5-yl)vinyl]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, and it was first disclosed in the patent numbered EP0175610. Cefditoren pivoxil, the chemical structure of which is shown in formula 1, is indicated for the treatment of the infections caused by gram positive and gram negative bacteria.
  • Cefditoren pivoxil is the ester form of the antibiotic known as cefditoren.
  • cefditoren pivoxil which is a form of pivaloyloxy methyl ester was produced. However, this caused that the substance, which is obtained, has a low water solubility.
  • Cefditoren pivoxil is available in oral dosage forms of 200 and 400 mg on the market.
  • the tablet forms comprising 200 and 400 mg active agent in a single dose are formulated with excipients, they become quite large in size and this made the use of this dosage form inconvenient in patients with dysphagia, particularly in pediatric and geriatric patients.
  • the suspension forms which have been alternatively developed to overcome said problems are not preferred since they have the potential of high and/or uncontrolled dose intake and are not physically and chemically stable.
  • the use of reliable and user-friendly water dispersible forms is suggested.
  • Cefditoren pivoxil has a low water solubility which is approximately less than 1 mg/ml.
  • the formulations comprising cefditoren pivoxil as an active agent cannot dissolve easily and disperse quickly in water. Due to these problems, sufficient amount of cefditoren active agent can not be absorbed and thus its bioavailability decreases.
  • the inventors have surprisingly found that the present problems in the prior art can be solved by the water dispersible powder, tablet and granule formulation prepared according to the subject of the present invention.
  • the present invention relates to the water dispersible powder, tablet and granules comprising cefditoren pivoxil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms of cefditoren pivoxil and/or combination thereof; their formulations and the procedures for their preparation.
  • compositions in the form of water dispersible powder, tablet or granule pertaining to the present invention are convenient for the patients with dysphagia, particularly in pediatric and geriatric patients.
  • the absorption and bioavailability of cefditoren pivoxil are found to be increased due to achieving a high solubility and rapid dissolution rate.
  • water dispersible powder, tablet and granule present in the text comprises effervescent tablets, effervescent granules, effervescent powders, water dispersible tablets, water dispersible powders, water dispersible granules, water soluble tablets, water soluble powders and water soluble granules.
  • the first aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule form comprising cefditoren pivoxil in which at least 65% diluent is used and diluent: cefditoren pivoxil ratio is in the range of 15 : 1 and 1 :1.
  • diluent: cefditoren pivoxil ratio is in the range of 15:1 to 1 : 1, preferably in the range of 12:1 to 4:1, most preferably in the range of 10: 1 to 5:1.
  • another aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule forms comprising cefditoren pivoxil in which at least 65% diluent is used and diluent: cefditoren pivoxil ratio is in the range of 15:1 to 1 : 1, preferably in the range of 12:1 to 4:1, most preferably in the range of 10:1 to 5:1.
  • Cefditoren pivoxil which is the subject of the present invention, can be present in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or a combination thereof in the water dispersible powder, tablet and granule formulations of the present invention.
  • cefditoren pivoxil is in crystal or amorphous form, more preferably cefditoren pivoxil is in amorphous form.
  • the diluent used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof.
  • sorbitol is used as diluent in the water dispersible powder, tablet and granule formulations pertaining to the present invention.
  • another aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule forms comprising cefditoren pivoxil in which at least 65% sorbitol is used and sorbitol: cefditoren ratio is in the range of 15:1 and 1 :1 by weight.
  • excipients selected from, but not limited to, a group comprising binders, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, sweeteners, taste regulating agents and optionally an effervescent couple can be used in the water dispersible formulation in addition to cefditoren pivoxil.
  • the binder that can be used in the water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
  • the lubricant that can be used in the water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
  • the disintegrant that can be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
  • the taste regulating agent and/or sweetener that can be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
  • sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention.
  • aspartame is used as the sweetener in the water dispersible powder, tablet and granule formulations pertaining to the present invention.
  • Cefditoren pivoxil is a molecule which has a bitter taste and it is so difficult to eliminate this unpleasant taste in the pharmaceutical formulations.
  • the inventors have found that the problem resulting from the bitter taste of cefditoren pivoxil is eliminated in the pharmaceutical formulations in which cefditoren pivoxil: sweetener ratio is in the range of 15:1 and 5:1, preferably 12:1 and 6:1 and the taste of water dispersible compositions comprising cefditoren pivoxil is found to be pleasant.
  • cefditoren pivoxil is the water dispersible cefditoren pivoxil formulations in which cefditoren pivoxil: sweetener ratio is in the range of 15: 1 and 5:1, preferably 12:1 and 6:1.
  • Effervescent acid that can optionally be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid.
  • Effervescent base that can optionally be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
  • cefditoren pivoxil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof can be used.
  • the water dispersible powder, tablet and granule formulation of the present invention can comprise 5-25% cefditoren pivoxil; 0-15% binder; 0-5% lubricant; 0-10% humectant, 0-20% disintegrant; 65-90% diluent; 0-15% basic agent; 0-20% acidic agent; 0,5-5% sweetener and/or taste regulating agent; 0.2-6% coloring and/or flavoring agent and 0-80% effervescent couple with respect to the total weight of unit dose.
  • the present invention relates to the processes which can be used for the preparation of water dispersible powder, tablet and granule formulations comprising pharmaceutically acceptable excipients in addition to cefditoren pivoxil as the active agent.
  • the pharmaceutical composition of the present invention can be prepared through a process which is comprised of dry blending or dry granulation or wet granulation of the components or a combination thereof and generally known standard techniques and manufacture procedures in technology.
  • the present invention relates to the preparation of a medicament comprising cefditoren pivoxil so as to be used in the treatment of infections caused by gram positive and gram negative bacteria.
  • the pharmaceutical composition prepared according to the present invention is used in the manufacture of a medicament so as to be used in upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin or soft tissue infections such as froncle, pyoderma, impetigo; in the treatment and prophylaxis of gonorrhea and lyme diseases.
  • upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis
  • lower respiratory tract infections such as pyelonephritis, cystitis and urethritis
  • skin or soft tissue infections such as froncle, pyoderma, impetigo
  • in the treatment and prophylaxis of gonorrhea and lyme diseases in the manufacture of a medicament so as to be used in upper respiratory infections such as
  • EXAMPLE 1 Formulation and process for the preparation of water dispersible granules
  • the process in scope of the present invention comprises granulating a mixture comprising cefditoren pivoxil and other excipients with the granulation solution comprising the coloring agent and the diluent through conventional wet and/or dry granulation methods in the prior art, then sieving the mixture; adding a flavoring agent and/or agents into the obtained granules, and optionally compressing the obtained mixture in tablet compressing machine.
  • EXAMPLE 2 Formulation and process for the preparation of effervescent tablets
  • the process in scope of the present invention comprises granulating a mixture comprising effervescent acid, effervescent base and sweetener with the granulation solution comprising binder and a solvent through conventional wet and/or dry granulation methods in the prior art, then sieving the mixture; adding cefditoren pivoxil, lubricant, coloring and flavoring agent into the obtained granules, and compressing the obtained mixture in tablet compressing machine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to water dispersible forms comprising cefditoren pivoxil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof.

Description

PHARMACEUTICAL COMPOSITIONS COMPRISING CEFDITOREN PIVOXIL
The present invention relates to water dispersible forms comprising cefditoren pivoxil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms and/or a combination thereof.
Background of the Invention:
Cefditoren pivoxil is a third generation cephalosporin, which has the chemical name (6R,7R)- pivaloyloxymethyl 7-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido]-3 -[(Z)-2-(4- methylthiazol-5-yl)vinyl]-8-oxo-5-thia-l-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, and it was first disclosed in the patent numbered EP0175610. Cefditoren pivoxil, the chemical structure of which is shown in formula 1, is indicated for the treatment of the infections caused by gram positive and gram negative bacteria.
Figure imgf000002_0001
Formula 1
Cefditoren pivoxil is the ester form of the antibiotic known as cefditoren. In order to increase the absorption of cefditoren in the body, cefditoren pivoxil which is a form of pivaloyloxy methyl ester was produced. However, this caused that the substance, which is obtained, has a low water solubility.
Cefditoren pivoxil is available in oral dosage forms of 200 and 400 mg on the market. When the tablet forms comprising 200 and 400 mg active agent in a single dose are formulated with excipients, they become quite large in size and this made the use of this dosage form inconvenient in patients with dysphagia, particularly in pediatric and geriatric patients. The suspension forms which have been alternatively developed to overcome said problems are not preferred since they have the potential of high and/or uncontrolled dose intake and are not physically and chemically stable. Alternatively, the use of reliable and user-friendly water dispersible forms is suggested. Cefditoren pivoxil has a low water solubility which is approximately less than 1 mg/ml. Accordingly, the formulations comprising cefditoren pivoxil as an active agent cannot dissolve easily and disperse quickly in water. Due to these problems, sufficient amount of cefditoren active agent can not be absorbed and thus its bioavailability decreases.
As it is seen, new formulations comprising cefditoren pivoxil are required to be developed in order to provide new dosage forms which are easily swallowed by pediatric and geriatric patients, which are easily dissolved and which are quickly dispersed in water during their usages.
The inventors have surprisingly found that the present problems in the prior art can be solved by the water dispersible powder, tablet and granule formulation prepared according to the subject of the present invention.
Description of the Invention:
The present invention relates to the water dispersible powder, tablet and granules comprising cefditoren pivoxil and/or pharmaceutically acceptable salts, hydrates, solvates, esters, amorphous and crystal forms of cefditoren pivoxil and/or combination thereof; their formulations and the procedures for their preparation. Surprisingly, it has been found that the water dispersible powder, tablet and granule formulations comprising cefditoren pivoxil in which at least 65% of diluent is used and diluent: cefditoren pivoxil ratio is in the range of 15:1 and 1 :1, dissolve in water entirely and disperse in 2-4 minutes.
Accordingly, pharmaceutical formulations in the form of water dispersible powder, tablet or granule pertaining to the present invention are convenient for the patients with dysphagia, particularly in pediatric and geriatric patients. Moreover, the absorption and bioavailability of cefditoren pivoxil are found to be increased due to achieving a high solubility and rapid dissolution rate.
The term "water dispersible powder, tablet and granule" present in the text comprises effervescent tablets, effervescent granules, effervescent powders, water dispersible tablets, water dispersible powders, water dispersible granules, water soluble tablets, water soluble powders and water soluble granules. Accordingly, the first aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule form comprising cefditoren pivoxil in which at least 65% diluent is used and diluent: cefditoren pivoxil ratio is in the range of 15 : 1 and 1 :1.
According to another aspect, diluent: cefditoren pivoxil ratio is in the range of 15:1 to 1 : 1, preferably in the range of 12:1 to 4:1, most preferably in the range of 10: 1 to 5:1.
According to this, another aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule forms comprising cefditoren pivoxil in which at least 65% diluent is used and diluent: cefditoren pivoxil ratio is in the range of 15:1 to 1 : 1, preferably in the range of 12:1 to 4:1, most preferably in the range of 10:1 to 5:1.
Cefditoren pivoxil, which is the subject of the present invention, can be present in the form of its solvates, hydrates, esters, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or a combination thereof in the water dispersible powder, tablet and granule formulations of the present invention. Preferably cefditoren pivoxil is in crystal or amorphous form, more preferably cefditoren pivoxil is in amorphous form.
The diluent used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising calcium carbonate, calcium sulphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof. Preferably sorbitol is used as diluent in the water dispersible powder, tablet and granule formulations pertaining to the present invention.
According to this, another aspect of the present invention is the water dispersible formulations formulated in powder, tablet or granule forms comprising cefditoren pivoxil in which at least 65% sorbitol is used and sorbitol: cefditoren ratio is in the range of 15:1 and 1 :1 by weight.
Various excipients selected from, but not limited to, a group comprising binders, lubricants, humectants, disintegrants, diluents, basic agents, acidic agents, sweeteners, taste regulating agents and optionally an effervescent couple can be used in the water dispersible formulation in addition to cefditoren pivoxil. The binder that can be used in the water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone or combinations thereof.
The lubricant that can be used in the water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
The disintegrant that can be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate and starch or combinations thereof.
The taste regulating agent and/or sweetener that can be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from, but not limited to, a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, maltose, sorbitol, saccharine, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof. Preferably, sucrose, aspartame, sodium chloride or a combination thereof is used in the formulations according to the present invention. Preferably, aspartame is used as the sweetener in the water dispersible powder, tablet and granule formulations pertaining to the present invention.
Cefditoren pivoxil is a molecule which has a bitter taste and it is so difficult to eliminate this unpleasant taste in the pharmaceutical formulations. The inventors have found that the problem resulting from the bitter taste of cefditoren pivoxil is eliminated in the pharmaceutical formulations in which cefditoren pivoxil: sweetener ratio is in the range of 15:1 and 5:1, preferably 12:1 and 6:1 and the taste of water dispersible compositions comprising cefditoren pivoxil is found to be pleasant. According to this, another aspect of the present invention is the water dispersible cefditoren pivoxil formulations in which cefditoren pivoxil: sweetener ratio is in the range of 15: 1 and 5:1, preferably 12:1 and 6:1.
Effervescent acid that can optionally be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid.
Effervescent base that can optionally be used in water dispersible powder, tablet and granule formulations pertaining to the present invention can be selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
In the water dispersible powder, tablet and granule formulation of the present invention, cefditoren pivoxil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof can be used.
The water dispersible powder, tablet and granule formulation of the present invention can comprise 5-25% cefditoren pivoxil; 0-15% binder; 0-5% lubricant; 0-10% humectant, 0-20% disintegrant; 65-90% diluent; 0-15% basic agent; 0-20% acidic agent; 0,5-5% sweetener and/or taste regulating agent; 0.2-6% coloring and/or flavoring agent and 0-80% effervescent couple with respect to the total weight of unit dose.
In another aspect, the present invention relates to the processes which can be used for the preparation of water dispersible powder, tablet and granule formulations comprising pharmaceutically acceptable excipients in addition to cefditoren pivoxil as the active agent.
The pharmaceutical composition of the present invention can be prepared through a process which is comprised of dry blending or dry granulation or wet granulation of the components or a combination thereof and generally known standard techniques and manufacture procedures in technology.
In another aspect, the present invention relates to the preparation of a medicament comprising cefditoren pivoxil so as to be used in the treatment of infections caused by gram positive and gram negative bacteria.
According to another aspect of the present invention, the pharmaceutical composition prepared according to the present invention is used in the manufacture of a medicament so as to be used in upper respiratory infections such as ear, nose, throat, otitis media, sinusitis, tonsillitis, pharyngitis; lower respiratory tract infections such as pyelonephritis, cystitis and urethritis; skin or soft tissue infections such as froncle, pyoderma, impetigo; in the treatment and prophylaxis of gonorrhea and lyme diseases.
EXAMPLE 1 : Formulation and process for the preparation of water dispersible granules
Figure imgf000007_0001
According to this, the process in scope of the present invention comprises granulating a mixture comprising cefditoren pivoxil and other excipients with the granulation solution comprising the coloring agent and the diluent through conventional wet and/or dry granulation methods in the prior art, then sieving the mixture; adding a flavoring agent and/or agents into the obtained granules, and optionally compressing the obtained mixture in tablet compressing machine.
EXAMPLE 2: Formulation and process for the preparation of effervescent tablets
Figure imgf000007_0002
According to this, the process in scope of the present invention comprises granulating a mixture comprising effervescent acid, effervescent base and sweetener with the granulation solution comprising binder and a solvent through conventional wet and/or dry granulation methods in the prior art, then sieving the mixture; adding cefditoren pivoxil, lubricant, coloring and flavoring agent into the obtained granules, and compressing the obtained mixture in tablet compressing machine.

Claims

CLAIMS:
1. A water dispersible formulation formulated in powder, tablet or granule form comprising cefditoren pivoxil characterized in that at least 65% diluent is used with respect to the total weight of the unit dosage and diluent: cefditoren ratio is in the range of 15: 1 and 1 :1.
2. The pharmaceutical composition according to claim 1, wherein diluent: cefditoren ratio is in the range of 12: 1 to 4: 1.
3. The pharmaceutical composition according to claim 2, wherein diluent: cefditoren ratio is in the range of 10:1 to 5:1.
4. The pharmaceutical composition according to claim 1, wherein cefditoren pivoxil that is used as the active agent can be in the form of its solvates, hydrates, enantiomers, racemates, organic salts, inorganic salts, polymorphs, crystal and amorphous forms or in free form and/or a combination thereof.
5. The pharmaceutical composition according to claim 1, wherein diluent is selected from a group comprising calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium phosphate, calcium sulphate, microcrystalline cellulose, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, sodium chloride, sorbitol, starch and xylitol or combinations thereof.
6. The pharmaceutical composition according to claim 5, wherein sorbitol is used as diluent.
7. The pharmaceutical composition according to claim 1, wherein said composition further comprises other pharmaceutically acceptable excipients in addition to diluent that is used together with cefditoren pivoxil
8. The pharmaceutical composition according to claim 7, wherein said composition comprises one or more binders, lubricant, humectant, disintegrant, basic agent, acidic agent, taste regulating agent and optionally effervescent couple in addition to cefditoren pivoxil that is used as the active agent.
9. The formulation according to claim 8, wherein binder is selected from a group comprising ethyl cellulose, gelatine, hydroxyethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hypromellose, magnesium aluminum silicate, methyl cellulose, povidone.
10. The formulation according to claim 8, wherein lubricant is selected from a group comprising calcium stearate, magnesium stearate, polyethylene glycol, PEG 6000, polyvinyl alcohol, potassium benzoate, sodium benzoate.
11. The formulation according to claim 8, wherein disintegrant is selected from a group comprising carboxymethyl cellulose calcium, carboxymethylcellulose sodium, microcrystalline cellulose, silicon dioxide, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, methyl cellulose, povidone, magnesium aluminum silicate, starch or combinations thereof.
12. The formulation according to claim 8, wherein taste regulating agent and/or sweetener is selected from a group comprising acesulfame, aspartame, dextrose, fructose, glucose, lactitol, maltitol, sorbitol, saccharine sodium, sodium cyclamate, sucralose, sodium chloride, potassium chloride, sucrose, xylitol or combinations thereof.
13. The formulation according to claim 12, wherein taste regulating agent and/or sweetener is selected from sucrose, aspartame, sodium chloride or a combination thereof.
14. The formulation according to claim 13, wherein aspartame is used as taste regulating agent and/or sweetener.
15. The formulation according to claim 12, wherein cefditoren pivoxil: sweetener ratio is in the range of 15:1 and 5:1.
16. The formulation according to claim 15, wherein cefditoren pivoxil: sweetener ratio is in the range of 12:1 and 6: 1.
17. The formulation according to claim 8, wherein effervescent acid that is optionally used is selected from organic acids such as citric acid, tartaric acid, malic acid, fumaric acid, ascorbic acid, adipic acid and succinic acid.
18. The formulation according to claim 8, wherein effervescent base that is optionally used is selected from basic agents such as sodium hydrogen carbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, sodium glycine carbonate, lysine carbonate, arginine carbonate and calcium carbonate.
19. The formulation according to claim 1, wherein cefditoren pivoxil or its pharmaceutically acceptable salts, hydrates, solvates or combinations thereof is used in said formulation.
20. The pharmaceutical composition according to claim 1, wherein said composition comprises 5-25 % cefditoren; 0-15% binder; 0-5% lubricant; 0-10% humectant, 0-20% disintegrant; 65-90% diluent; 0-15% basic agent; 0-20% acidic agent; 0,5-5% sweetener and/or taste regulating agent; 0.2-6% coloring and/or flavoring agent and 0-80% effervescent couple with respect to the total amount of unit dose.
21. The method for the preparation of a pharmaceutical composition according to claim 1, wherein said method comprises a process of dry blending or dry granulation or wet granulation of the components or a combination thereof, and generally known standard techniques and manufacture procedures in technology.
PCT/TR2011/000125 2010-05-04 2011-05-02 Pharmaceutical compositions comprising cefditoren pivoxil WO2011139251A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11724820.3A EP2566451B1 (en) 2010-05-04 2011-05-02 Pharmaceutical compositions comprising cefditoren pivoxil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201003548 2010-05-04
TR2010/03548 2010-05-04

Publications (1)

Publication Number Publication Date
WO2011139251A1 true WO2011139251A1 (en) 2011-11-10

Family

ID=44202158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000125 WO2011139251A1 (en) 2010-05-04 2011-05-02 Pharmaceutical compositions comprising cefditoren pivoxil

Country Status (2)

Country Link
EP (1) EP2566451B1 (en)
WO (1) WO2011139251A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103860563A (en) * 2012-12-18 2014-06-18 四川科伦药业股份有限公司 Cefditoren sodium containing-pharmaceutical composition
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
US11576855B2 (en) 2014-09-17 2023-02-14 Steerlife India Private Limited Effervescent composition and method of making it

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175610A2 (en) 1984-09-07 1986-03-26 Meiji Seika Kaisha Ltd. New cephalosporin compounds and the production thereof
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2005055986A1 (en) * 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research Taste masked pharmaceutical composition comprising ph sensitive polymer
CN1846702A (en) * 2006-05-10 2006-10-18 楼剑波 Dispersed cefditoren pivoxil tablet and its prepn process
JP2007106684A (en) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd Antibacterial pharmaceutical composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175610A2 (en) 1984-09-07 1986-03-26 Meiji Seika Kaisha Ltd. New cephalosporin compounds and the production thereof
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
JP2004043475A (en) * 2002-07-08 2004-02-12 Sankyo Co Ltd Oral cephalosporin preparation
WO2005055986A1 (en) * 2003-12-15 2005-06-23 Council Of Scientific & Industrial Research Taste masked pharmaceutical composition comprising ph sensitive polymer
JP2007106684A (en) * 2005-10-11 2007-04-26 Sawai Pharmaceutical Co Ltd Antibacterial pharmaceutical composition
CN1846702A (en) * 2006-05-10 2006-10-18 楼剑波 Dispersed cefditoren pivoxil tablet and its prepn process

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103860563A (en) * 2012-12-18 2014-06-18 四川科伦药业股份有限公司 Cefditoren sodium containing-pharmaceutical composition
US11576855B2 (en) 2014-09-17 2023-02-14 Steerlife India Private Limited Effervescent composition and method of making it
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof

Also Published As

Publication number Publication date
EP2566451A1 (en) 2013-03-13
EP2566451B1 (en) 2014-09-10

Similar Documents

Publication Publication Date Title
EP2528594B1 (en) Effervescent formulations comprising second generation cephalosporin
WO2011142731A2 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2012060785A1 (en) Production method for tablets comprising cephalosporin
EP2566448B1 (en) Efervescent formulations comprising cefdinir
EP2566451B1 (en) Pharmaceutical compositions comprising cefditoren pivoxil
EP2566449B1 (en) Pharmaceutical compositions comprising ceftibuten
WO2011142730A1 (en) Pharmaceutical composition comprising cefixime and clavulanic acid derivative compound
US20130129791A1 (en) Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
EP2515850B1 (en) Pharmaceutical compositions comprising cefdinir as an active agent
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
WO2011093831A2 (en) Effervescent formulations comprising cefprozil as active agent
WO2012060786A2 (en) Cefpodoxime proxetil formulations comprising viscosity agent
EP2608776A2 (en) Cefpodoxime proxetil formulations
WO2011078828A1 (en) Pharmaceutical composition with high purity
WO2011093821A1 (en) Effervescent formulations comprising cefdinir and clavulanic acid
EP2566450A2 (en) Pharmaceutical compositions comprising cefetamet
EP2515859A1 (en) Rapidly dispersing effervescent formulation
WO2012060787A1 (en) Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium
EP2663289A2 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
WO2012078121A2 (en) Solid oral dosage form comprising cefdinir
WO2013109201A1 (en) Pharmaceutical compositions comprising cefprozil and clavulanic acid
WO2012060789A2 (en) Production method for cefdinir formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11724820

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011724820

Country of ref document: EP